Literature DB >> 2211628

Characterization of an active single polypeptide form of the human immunodeficiency virus type 1 protease.

C L DiIanni1, L J Davis, M K Holloway, W K Herber, P L Darke, N E Kohl, R A Dixon.   

Abstract

The pepsin-like aspartyl proteases consist of a single polypeptide chain with topologically similar amino- and carboxyl-terminal domains, each of which contributes 1 aspartic acid residue to the active site. This structure has been proposed to have evolved by gene duplication and fusion from a dimeric enzyme composed of two identical polypeptide chains, such as the aspartyl protease (PRT) of human immunodeficiency virus type 1 (HIV-1). To determine if a single polypeptide form of the HIV-1 protease would be enzymatically active, two protease coding regions were linked to form a dimeric gene (pFGGP). Expression of this gene in Escherichia coli yielded a protein with the expected molecular mass of 22 kDa. The in vitro kinetic parameters of PRT and FGGP (where FGGP is the single polypeptide form of the HIV-1 protease with 2 glycine residues connecting the two subunits) for three peptide substrates are similar. Construction and analysis of a CheY-GAG-FGGP fusion protein demonstrated that FGGP is capable of precursor processing in vivo. Mutation of one or both of the active site aspartates to either asparagine or glutamate rendered the enzyme inactive, demonstrating that both active site aspartate residues are required for enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2211628

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer.

Authors:  Y S Cheng; F H Yin; S Foundling; D Blomstrom; C A Kettner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 2.  Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes.

Authors:  W G Dougherty; B L Semler
Journal:  Microbiol Rev       Date:  1993-12

3.  Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation.

Authors:  H G Kräusslich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Importance of the N terminus of rous sarcoma virus protease for structure and enzymatic function.

Authors:  G W Schatz; J Reinking; J Zippin; L K Nicholson; V M Vogt
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity.

Authors:  H G Kräusslich
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

6.  Therapeutic effect of Gag-nuclease fusion protein on retrovirus-infected cell cultures.

Authors:  G Schumann; L Qin; A Rein; G Natsoulis; J D Boeke
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.

Authors:  X Wu; H Liu; H Xiao; J A Conway; J C Kappes
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases.

Authors:  L M Babé; J Rosé; C S Craik
Journal:  Protein Sci       Date:  1992-10       Impact factor: 6.725

10.  Human immunodeficiency virus type 1 and type 2 protease monomers are functionally interchangeable in the dimeric enzymes.

Authors:  C E Patterson; R Seetharam; C A Kettner; Y S Cheng
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.